Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07, 8.01, 9.01 · 8-K

Jupiter Neurosciences, Inc.

JUNSNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders · Other Events

Item 5.07 Submission of Matters to a Vote of Security Holders. Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on July 22, 2026. In connection with the Annual Meeting, proxies were solicited pursuant to the Securities Exchange Act of 1934, as amended.…

Filed Jul 27, 2026Accepted Jul 27, 2026, 9:00 AM EDTCIK 1679628Accession 0001493152-26-034724
Share

Company context

Current securities

Recent company filings

  1. S-8 filingOct 13, 2026
  2. S-3 filingSep 25, 2026
  3. SCHEDULE 13G - filed by PharmAla Biotech Holdings Inc. regarding JUPITER NEUROSCIENCES, INC.Sep 22, 2026
  4. D filingSep 4, 2026
  5. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearSep 3, 2026

Registered securities in this filing

JUPITER NEUROSCIENCES, INC. · 8-K · Filed 2026-07-27

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
JUNS
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-07-22

Dimensions: Not supplied

Accession 000149315226034724 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.07, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. Jupiter Neurosciences, Inc. (“Jupiter” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on July 22, 2026. In connection with the Annual Meeting, proxies were solicited pursuant to the Securities Exchange Act of 1934, as amended. At the close of business on June 15, 2026, the record date for the Annual Meeting (the “Record Date”), there were 48,224,110 shares of common stock issued and outstanding, which constituted all of the issued and outstanding capital stock of the Company as of the Record Date. At the Annual Meeting, 28,456,277 of the Company’s 48,224,110 outstanding shares of common stock entitled to vote as of the Record Date, or approximately 59%, were represented by proxy or in person (virtually), and, therefore, a quorum was present. The following are the voting results for the items of business considered and voted upon at the Annual Meeting, all of which were described in Jupiter’s Notice of 2026 Annual Meeting of Stockholders and Proxy Statement, filed with the Securities and Exchange Commission on June 22, 2026, as amended. The stockholders elected each of Jupiter’s seven director nominees, each to serve until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified. In connection with his appointment, Dr. Andrew J. Cutler was also appointed to serve as a member of the Compensation Committee of our board of directors (the “Board”), effective on the same date as his appointment to the Board. The vote tabulation with respect to the nominees was as follows: NOMINEE VOTES AUTHORITY BROKER FOR WITHHELD NON-VOTES ────────────────────────────────────────────────────────────────────────── Christer Rosén 18,867,403 209,747 9,379,127 Marshall Hayward, Ph. D. 18,919,082 158,068 9,379,127 Alison D. Silva 18,864,702 212,448 9,379,127 Nicholas H. Hemmerly 18,869,256 207,894 9,379,127 Tomas J. Philipson 18,923,747 153,403 9,379,127 Andrew J. Cutler, M.D. 18,899,261 177,889 9,379,127 Holger Weis 18,920,866 156,284 9,379,127 The selection of Cherry Bekaert LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The results of the vote were as follows: ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── VOTES VOTES VOTES BROKER FOR AGAINST ABSTAINED NON-VOTES ───────────────────────────────────────────────────────── 28,070,928 286,851 98,498 0 The stockholders approved an amendment to our 2025 Equity Incentive Plan (the “2025 Plan”) to increase the number shares of common stock available for sale under the 2025 Plan by 5,250,000 shares of common stock. The results of the vote were as follows: VOTES VOTES VOTES BROKER NON-VOTES FOR AGAINST ABSTAINED ─────────────────────────────────────────────────────────── 16,518,361 2,416,038 142,751 9,379,127 The stockholders approved an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1:10 and not more than 1:100 (the “Reverse Stock Split”), such ratio and the implementation and timing of such Reverse Stock Split to be determined in the discretion of our Board. The results of the vote were as follows: VOTES VOTES VOTES BROKER FOR AGAINST ABSTAINED NON-VOTES ─────────────────────────────────────────────────────────── 24,398,822 4,008,323 49,132 0
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events As previously disclosed, in connection with the Company’s Standby Equity Purchase Agreement dated October 24, 2025 (the “SEPA”) with YA II PN, Ltd. (“Yorkville”), pursuant to which the Company has the right, but not the obligation, to issue and sell to Yorkville, from time to time, up to $20.0 million of shares of its common stock (the “SEPA Shares”), Yorkville provided the Company with advance funds of $6.0 million funded in two tranches (each a “Prepaid Advance”), in exchange for its issuance of convertible promissory notes (each, a “Convertible Note” and collectively, the “Convertible Notes”). Each Prepaid Advance is expected to be repaid through the issuance of SEPA Shares at a price per share determined in accordance with the terms of the SEPA, which is generally based on a discount to the prevailing market price of our common stock during a specified pricing period, unless earlier repaid in cash at our option, subject to the terms of the SEPA. Accordingly, the number of SEPA Shares issuable upon settlement of any Prepaid Advance will depend on the market price of our common stock at the time of such settlement and cannot be determined at the time such Prepaid Advance is made or thereafter until settlement. On October 27, 2025, the Company received the first tranche of the Prepaid Advance in the amount of $3,720,000 and issued to Yorkville a Convertible Note in the principal amount of $4.0 million (the “First Convertible Note”), which was issued with an original issue discount of 7.0%. The First Convertible Note is initially convertible into shares of the Company’s common stock at a fixed conversion price of $1.50 per share. Subsequently, upon satisfaction of the applicable conditions, on December 23, 2025 the Company received the second tranche of the Prepaid Advance in the amount of $1,860,000 and issued to Yorkville a Convertible Note in the principal amount of $2.0 million (the “Second Convertible Note” and, together with the First Convertible Note, the “Convertible Notes”), which was issued with an original issue discount of 7.0% and is initially convertible into shares of our common stock at a fixed conversion price of $1.50 per share. As of the date of this Current Report on Form 8-K, approximately $1.5 million aggregate principal amount of the Convertible Notes remains outstanding. The Company has issued and sold approximately 12.5 million SEPA Shares to Yorkville pursuant to the SEPA, including SEPA Shares issued in connection with the settlement of Prepaid Advances and upon conversion of the Convertible Notes, for aggregate net proceeds to the Company of approximately $4.1 million. We may continue to issue SEPA Shares to Yorkville pursuant to the SEPA, including in connection with any outstanding or future Prepaid Advances or conversions of Convertible Notes, subject to the terms and conditions of the SEPA. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock, nor shall there be any sale of shares of common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.